Skip to content

Effects of cannabis use on outcomes of psychotic disorders: systematic review

Stanley Zammit, Theresa HM Moore, Anne Lingford‐hughes, Thomas R. E. Barnes, Peter Brian Jones, Margaret Burke, Glyn Lewis

The British Journal of Psychiatry October 31, 2008 DOI: 10.1192/bjp.bp.107.046375 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Longitudinal Peer reviewed
Population People with psychotic disorders, as examined in 13 longitudinal studies
Topics Cannabis
Citations 275
Key findings Cannabis use was consistently associated with increased relapse and non-adherence in people with psychotic disorders, but associations with other outcomes were more disparate. Because few studies adjusted for baseline illness severity, alcohol, or other confounders, and adjustment often substantially attenuated results, the authors conclude that confidence that most associations are specifically due to cannabis is low.

Abstract

Background: It is unclear if research findings support clinical opinion that cannabis use leads to worse outcomes in people with psychosis, or whether this impression is confounded by other factors.

Aims: To systematically review the evidence pertaining to whether cannabis affects outcome of psychotic disorders.

Method: We searched 10 relevant databases (to November 2006), reference lists of included studies and contacted experts. We included 13 longitudinal studies from 15,303 references. Data extraction and quality assessment were conducted independently and in duplicate.

Results: Cannabis use was consistently associated with increased relapse and non-adherence. Associations with other outcome measures were more disparate. Few studies adjusted for baseline illness severity, and most made no adjustment for alcohol, or other potentially important confounders. Adjusting for even a few confounders often resulted in substantial attenuation of results.

Conclusions: Confidence that most associations reported were specifically due to cannabis is low. Despite clinical opinion, it remains important to establish whether cannabis is harmful, what outcomes are particularly susceptible, and how such effects are mediated. Studies to examine this further are eminently feasible.

Comparable studies

Other systematic reviews and meta-analyses on cannabis, most cited first.

Study Year Design Participants
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... 2010 Meta-analysis and cross-sectional observational study n = 700
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 Systematic review
Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies 2009 Systematic review
Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia 2016 Systematic review
Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties 2020 Systematic review

Citations in the library

Explore topics